Browsing Tag
Sunovion Pharmaceuticals
5 posts
Lupin launches Lurasidone Hydrochloride in US, targeting $4.2bn bipolar depression market
Lupin launches Lurasidone Hydrochloride Tablets in the US, entering a $4.2B bipolar depression market with a full range of strengths.
Lupin to acquire rights to Brovana and Xopenex HFA for $75m
Lupin Limited has agreed to acquire all rights to a couple of inhalation medicines, namely Brovana (arformoterol tartrate)…
Lupin Limited launches generic of Arformoterol Tartrate in US
Lupin Limited said that it has launched the authorized generic version of Brovana (arformoterol tartrate) Inhalation Solution 15…
Can Alembic Pharmaceuticals challenge Latuda with its FDA-approved Lurasidone Hydrochloride Tablets?
Find out how Alembic Pharmaceuticals’ FDA approval for Lurasidone Hydrochloride Tablets positions the drugmaker in the $3.7B bipolar depression market.
FDA declines approval for Sunovion’s ADHD drug dasotraline, citing need for more data
In a regulatory setback, the U.S. Food and Drug Administration (FDA) has decided not to approve Sunovion Pharmaceuticals’…